500 related articles for article (PubMed ID: 18413796)
21. Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II.
Dituri F; Mazzocca A; Fernando J; Peidrò FJ; Papappicco P; Fabregat I; De Santis F; Paradiso A; Sabbà C; Giannelli G
PLoS One; 2013; 8(6):e67109. PubMed ID: 23826206
[TBL] [Abstract][Full Text] [Related]
22. PDGF receptor-α promotes TGF-β signaling in hepatic stellate cells via transcriptional and posttranscriptional regulation of TGF-β receptors.
Liu C; Li J; Xiang X; Guo L; Tu K; Liu Q; Shah VH; Kang N
Am J Physiol Gastrointest Liver Physiol; 2014 Oct; 307(7):G749-59. PubMed ID: 25169976
[TBL] [Abstract][Full Text] [Related]
23. An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast cancer.
Rausch MP; Hahn T; Ramanathapuram L; Bradley-Dunlop D; Mahadevan D; Mercado-Pimentel ME; Runyan RB; Besselsen DG; Zhang X; Cheung HK; Lee WC; Ling LE; Akporiaye ET
Anticancer Res; 2009 Jun; 29(6):2099-109. PubMed ID: 19528470
[TBL] [Abstract][Full Text] [Related]
24. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
Baker CH; Solorzano CC; Fidler IJ
Cancer Res; 2002 Apr; 62(7):1996-2003. PubMed ID: 11929816
[TBL] [Abstract][Full Text] [Related]
25. EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung.
Park CY; Son JY; Jin CH; Nam JS; Kim DK; Sheen YY
Eur J Cancer; 2011 Nov; 47(17):2642-53. PubMed ID: 21852112
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling.
Matzke-Ogi A; Jannasch K; Shatirishvili M; Fuchs B; Chiblak S; Morton J; Tawk B; Lindner T; Sansom O; Alves F; Warth A; Schwager C; Mier W; Kleeff J; Ponta H; Abdollahi A; Orian-Rousseau V
Gastroenterology; 2016 Feb; 150(2):513-25.e10. PubMed ID: 26597578
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R
Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919
[TBL] [Abstract][Full Text] [Related]
28. EW-7203, a novel small molecule inhibitor of transforming growth factor-β (TGF-β) type I receptor/activin receptor-like kinase-5, blocks TGF-β1-mediated epithelial-to-mesenchymal transition in mammary epithelial cells.
Park CY; Kim DK; Sheen YY
Cancer Sci; 2011 Oct; 102(10):1889-96. PubMed ID: 21707864
[TBL] [Abstract][Full Text] [Related]
29. Transforming growth factor beta receptor I inhibitor sensitizes drug-resistant pancreatic cancer cells to gemcitabine.
Kim YJ; Hwang JS; Hong YB; Bae I; Seong YS
Anticancer Res; 2012 Mar; 32(3):799-806. PubMed ID: 22399597
[TBL] [Abstract][Full Text] [Related]
30. Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer.
Zhang B; Halder SK; Zhang S; Datta PK
Cancer Lett; 2009 May; 277(1):114-20. PubMed ID: 19147275
[TBL] [Abstract][Full Text] [Related]
31. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation.
Rowland-Goldsmith MA; Maruyama H; Kusama T; Ralli S; Korc M
Clin Cancer Res; 2001 Sep; 7(9):2931-40. PubMed ID: 11555612
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation.
Mazzocca A; Fransvea E; Lavezzari G; Antonaci S; Giannelli G
Hepatology; 2009 Oct; 50(4):1140-51. PubMed ID: 19711426
[TBL] [Abstract][Full Text] [Related]
33. TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo.
Bouquet F; Pal A; Pilones KA; Demaria S; Hann B; Akhurst RJ; Babb JS; Lonning SM; DeWyngaert JK; Formenti SC; Barcellos-Hoff MH
Clin Cancer Res; 2011 Nov; 17(21):6754-65. PubMed ID: 22028490
[TBL] [Abstract][Full Text] [Related]
34. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
Herbertz S; Sawyer JS; Stauber AJ; Gueorguieva I; Driscoll KE; Estrem ST; Cleverly AL; Desaiah D; Guba SC; Benhadji KA; Slapak CA; Lahn MM
Drug Des Devel Ther; 2015; 9():4479-99. PubMed ID: 26309397
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice.
Baker CH; Trevino JG; Summy JM; Zhang F; Caron A; Nesbit M; Gallick GE; Fidler IJ
Int J Oncol; 2006 Jul; 29(1):125-38. PubMed ID: 16773192
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
Wendt MK; Schiemann WP
Breast Cancer Res; 2009; 11(5):R68. PubMed ID: 19740433
[TBL] [Abstract][Full Text] [Related]
37. LY2109761 reduces TGF-β1-induced collagen production and contraction in hypertrophic scar fibroblasts.
Wei G; Xu Q; Liu L; Zhang H; Tan X; Zhang C; Han C; Guo Y; Han G; Zhang C
Arch Dermatol Res; 2018 Oct; 310(8):615-623. PubMed ID: 30046895
[TBL] [Abstract][Full Text] [Related]
38. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
[TBL] [Abstract][Full Text] [Related]
39. Neutralizing murine TGFβR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis.
Ostapoff KT; Cenik BK; Wang M; Ye R; Xu X; Nugent D; Hagopian MM; Topalovski M; Rivera LB; Carroll KD; Brekken RA
Cancer Res; 2014 Sep; 74(18):4996-5007. PubMed ID: 25060520
[TBL] [Abstract][Full Text] [Related]
40. TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelo-monocytic leukaemic cells co-cultured with stromal cells.
Xu Y; Tabe Y; Jin L; Watt J; McQueen T; Ohsaka A; Andreeff M; Konopleva M
Br J Haematol; 2008 Jun; 142(2):192-201. PubMed ID: 18492113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
